These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11916234)

  • 1. Benign breast disease and breast cancer risk: potential role for antiestrogens.
    Schnitt SJ
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4419s-4422s; discussion 4411s-4412s. PubMed ID: 11916234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study.
    Collins LC; Baer HJ; Tamimi RM; Connolly JL; Colditz GA; Schnitt SJ
    Cancer; 2006 Sep; 107(6):1240-7. PubMed ID: 16902983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study.
    Cummings SR; Lee JS; Lui LY; Stone K; Ljung BM; Cauleys JA
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1047-51. PubMed ID: 15894651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplicity of benign breast lesions is a risk factor for progression to breast cancer.
    Worsham MJ; Raju U; Lu M; Kapke A; Cheng J; Wolman SR
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5474-9. PubMed ID: 17875777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study.
    Collins LC; Baer HJ; Tamimi RM; Connolly JL; Colditz GA; Schnitt SJ
    Cancer; 2007 Jan; 109(2):180-7. PubMed ID: 17154175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies.
    Sanders ME; Page DL; Simpson JF; Schuyler PA; Dale Plummer W; Dupont WD
    Cancer; 2006 Apr; 106(7):1453-61. PubMed ID: 16502407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Contraception without risk of breast disease: epidemiologic and physiopathologic arguments].
    Le Coutour X
    NPN Med; 1985 Apr; 5(88):471-6. PubMed ID: 12315304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
    Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
    Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of breast cancer in women with benign breast disease.
    Hutchinson WB; Thomas DB; Hamlin WB; Roth GJ; Peterson AV; Williams B
    J Natl Cancer Inst; 1980 Jul; 65(1):13-20. PubMed ID: 6930509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.
    Rohan TE; Negassa A; Chlebowski RT; Habel L; McTiernan A; Ginsberg M; Wassertheil-Smoller S; Page DL
    J Natl Cancer Inst; 2008 Apr; 100(8):563-71. PubMed ID: 18398105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Breakthrough in breast cancer chemoprevention].
    Kahán Z; Thurzó L
    Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in breast cancer risk factors according to the estrogen receptor level of the tumor.
    Hildreth NG; Kelsey JL; Eisenfeld AJ; LiVolsi VA; Holford TR; Fischer DB
    J Natl Cancer Inst; 1983 Jun; 70(6):1027-31. PubMed ID: 6574271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer risk in women with radial scars in benign breast biopsies.
    Berg JC; Visscher DW; Vierkant RA; Pankratz VS; Maloney SD; Lewis JT; Frost MH; Ghosh K; Degnim AC; Brandt KR; Vachon CM; Reynolds CA; Hartmann LC
    Breast Cancer Res Treat; 2008 Mar; 108(2):167-74. PubMed ID: 18297395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
    Dew JE; Wren BG; Eden JA
    Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival in primary breast cancer: correlation with estrogen and progesterone receptor assay results and adjuvant tamoxifen therapy.
    Chrapusta SJ; Giermek J; Pieńkowski T
    Med Sci Monit; 2004 Oct; 10(10):CR577-86. PubMed ID: 15448598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.